Company news

Axsome Therapeutics, Inc. news in 2025

Axsome Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

December 30, 2025

Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

December 30, 2025

Axsome Therapeutics to Participate in Upcoming Investor Conferences

November 19, 2025

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

November 5, 2025

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

November 5, 2025

Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 2, 2025

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

October 8, 2025

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

October 6, 2025

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

September 16, 2025

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 3, 2025

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

July 20, 2025

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

July 8, 2025

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

July 6, 2025

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

June 19, 2025

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

June 17, 2025

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders

June 15, 2025

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

June 11, 2025

Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

June 9, 2025

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia

June 8, 2025

Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

May 26, 2025

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

May 12, 2025

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

April 30, 2025

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

April 7, 2025

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

April 3, 2025

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

March 31, 2025

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

March 24, 2025

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

March 5, 2025

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

March 2, 2025

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

February 23, 2025

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 17, 2025

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

February 9, 2025

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

January 30, 2025

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

January 29, 2025

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

January 12, 2025

Calls in 2025

Decks in 2025